Literature DB >> 22956816

Antiphospholipase A2 receptor antibody titer and subclass in idiopathic membranous nephropathy.

Julia M Hofstra1, Hanna Debiec, Colin D Short, Timotheé Pellé, Robert Kleta, Peter W Mathieson, Pierre Ronco, Paul E Brenchley, Jack F Wetzels.   

Abstract

The phospholipase A(2) receptor (PLA(2)R) is the major target antigen in idiopathic membranous nephropathy. The technique for measuring antibodies against PLA(2)R and the relationship between antibody titer and clinical characteristics are not well established. Here, we measured anti-PLA(2)R (aPLA(2)R) antibody titer and subclass in a well defined cohort of 117 Caucasian patients with idiopathic membranous nephropathy and nephrotic-range proteinuria using both indirect immunofluorescence testing (IIFT) and ELISA. We assessed agreement between tests and correlated antibody titer with clinical baseline parameters and outcome. In this cohort, aPLA(2)R antibodies were positive in 74% and 72% of patients using IIFT and ELISA, respectively. Concordance between both tests was excellent (94% agreement, κ=0.85). Among 82 aPLA(2)R-positive patients, antibody titer significantly correlated with baseline proteinuria (P=0.02). Spontaneous remissions occurred significantly less frequently among patients with high antibody titers (38% versus 4% in the lowest and highest tertiles, respectively; P<0.01). IgG4 was the dominant subclass in the majority of patients. Titers of IgG4, but not IgG1 or IgG3, significantly correlated with the occurrence of spontaneous remission (P=0.03). In summary, these data show high agreement between IIFT and ELISA assessments of aPLA(2)R antibody titer and highlight the pathogenetic role of these antibodies, especially the IgG4 subclass, given the observed relationships between aPLA(2)R titer, baseline proteinuria, and outcome.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22956816      PMCID: PMC3458465          DOI: 10.1681/ASN.2012030242

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  17 in total

1.  Early-childhood membranous nephropathy due to cationic bovine serum albumin.

Authors:  Hanna Debiec; Florence Lefeu; Markus J Kemper; Patrick Niaudet; Georges Deschênes; Giuseppe Remuzzi; Tim Ulinski; Pierre Ronco
Journal:  N Engl J Med       Date:  2011-06-02       Impact factor: 91.245

2.  Antenatal membranous glomerulonephritis due to anti-neutral endopeptidase antibodies.

Authors:  Hanna Debiec; Vincent Guigonis; Béatrice Mougenot; Fabrice Decobert; Jean-Philippe Haymann; Albert Bensman; Georges Deschênes; Pierre M Ronco
Journal:  N Engl J Med       Date:  2002-06-27       Impact factor: 91.245

Review 3.  Secondary membranous glomerulonephritis.

Authors:  R J Glassock
Journal:  Nephrol Dial Transplant       Date:  1992       Impact factor: 5.992

Review 4.  Management of membranous nephropathy: when and what for treatment.

Authors:  Daniel Cattran
Journal:  J Am Soc Nephrol       Date:  2005-03-30       Impact factor: 10.121

5.  Anti-phospholipase A2 receptor antibody in membranous nephropathy.

Authors:  Weisong Qin; Laurence H Beck; Caihong Zeng; Zhaohong Chen; Shijun Li; Ke Zuo; David J Salant; Zhihong Liu
Journal:  J Am Soc Nephrol       Date:  2011-05-12       Impact factor: 10.121

6.  Autoimmunity in membranous nephropathy targets aldose reductase and SOD2.

Authors:  Marco Prunotto; Maria Luisa Carnevali; Giovanni Candiano; Corrado Murtas; Maurizio Bruschi; Emilia Corradini; Antonella Trivelli; Alberto Magnasco; Andrea Petretto; Laura Santucci; Silvia Mattei; Rita Gatti; Francesco Scolari; Peter Kador; Landino Allegri; Gian Marco Ghiggeri
Journal:  J Am Soc Nephrol       Date:  2010-02-11       Impact factor: 10.121

7.  PLA2R autoantibodies and PLA2R glomerular deposits in membranous nephropathy.

Authors:  Hanna Debiec; Pierre Ronco
Journal:  N Engl J Med       Date:  2011-02-17       Impact factor: 91.245

8.  Risk HLA-DQA1 and PLA(2)R1 alleles in idiopathic membranous nephropathy.

Authors:  Horia C Stanescu; Mauricio Arcos-Burgos; Alan Medlar; Detlef Bockenhauer; Anna Kottgen; Liviu Dragomirescu; Catalin Voinescu; Naina Patel; Kerra Pearce; Mike Hubank; Henry A F Stephens; Valerie Laundy; Sandosh Padmanabhan; Anna Zawadzka; Julia M Hofstra; Marieke J H Coenen; Martin den Heijer; Lambertus A L M Kiemeney; Delphine Bacq-Daian; Benedicte Stengel; Stephen H Powis; Paul Brenchley; John Feehally; Andrew J Rees; Hanna Debiec; Jack F M Wetzels; Pierre Ronco; Peter W Mathieson; Robert Kleta
Journal:  N Engl J Med       Date:  2011-02-17       Impact factor: 91.245

Review 9.  Idiopathic membranous nephropathy: outline and rationale of a treatment strategy.

Authors:  Peggy W G du Buf-Vereijken; Amanda J W Branten; Jack F M Wetzels
Journal:  Am J Kidney Dis       Date:  2005-12       Impact factor: 8.860

10.  M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy.

Authors:  Laurence H Beck; Ramon G B Bonegio; Gérard Lambeau; David M Beck; David W Powell; Timothy D Cummins; Jon B Klein; David J Salant
Journal:  N Engl J Med       Date:  2009-07-02       Impact factor: 91.245

View more
  126 in total

1.  Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy.

Authors:  Nicola M Tomas; Laurence H Beck; Catherine Meyer-Schwesinger; Barbara Seitz-Polski; Hong Ma; Gunther Zahner; Guillaume Dolla; Elion Hoxha; Udo Helmchen; Anne-Sophie Dabert-Gay; Delphine Debayle; Michael Merchant; Jon Klein; David J Salant; Rolf A K Stahl; Gérard Lambeau
Journal:  N Engl J Med       Date:  2014-11-13       Impact factor: 91.245

2.  An Indirect Immunofluorescence Method Facilitates Detection of Thrombospondin Type 1 Domain-Containing 7A-Specific Antibodies in Membranous Nephropathy.

Authors:  Elion Hoxha; Laurence H Beck; Thorsten Wiech; Nicola M Tomas; Christian Probst; Swantje Mindorf; Catherine Meyer-Schwesinger; Gunther Zahner; Phillip R Stahl; Ruth Schöpper; Ulf Panzer; Sigrid Harendza; Udo Helmchen; David J Salant; Rolf A K Stahl
Journal:  J Am Soc Nephrol       Date:  2016-07-19       Impact factor: 10.121

3.  Circulating antibodies against M-type phospholipase A2 receptor and thrombospondin type-1 domain-containing 7A in Chinese patients with membranous nephropathy.

Authors:  Caixia Tian; Lian Li; Tanxin Liu; Xin Qu; Yurong Qiu
Journal:  Int Urol Nephrol       Date:  2019-06-21       Impact factor: 2.370

4.  Can genetics risk-stratify patients with membranous nephropathy?

Authors:  Andrew S Bomback; Ali G Gharavi
Journal:  J Am Soc Nephrol       Date:  2013-07-05       Impact factor: 10.121

5.  Treatment-resistant PLA2R-negative membranous nephropathy responsive to low-density lipoprotein apheresis.

Authors:  James M Szymanski; Meryl Waldman; Cathy Conry-Cantilena; Kamille Aisha West
Journal:  J Clin Apher       Date:  2018-12-10       Impact factor: 2.821

6.  M-type phospholipase A2 receptor autoantibodies and renal function in patients with primary membranous nephropathy.

Authors:  Elion Hoxha; Sigrid Harendza; Hans Pinnschmidt; Ulf Panzer; Rolf A K Stahl
Journal:  Clin J Am Soc Nephrol       Date:  2014-09-29       Impact factor: 8.237

7.  Long-term outcomes of initial therapy for idiopathic membranous nephropathy.

Authors:  Masayo Sato; Takashi Takei; Takahito Moriyama; Mitsuyo Itabashi; Kosaku Nitta
Journal:  Clin Exp Nephrol       Date:  2016-12-20       Impact factor: 2.801

8.  The Most N-Terminal Region of THSD7A Is the Predominant Target for Autoimmunity in THSD7A-Associated Membranous Nephropathy.

Authors:  Larissa Seifert; Elion Hoxha; Anna M Eichhoff; Gunther Zahner; Silke Dehde; Linda Reinhard; Friedrich Koch-Nolte; Rolf A K Stahl; Nicola M Tomas
Journal:  J Am Soc Nephrol       Date:  2018-03-19       Impact factor: 10.121

9.  Membranous glomerulonephritis with crescents.

Authors:  Caroline M F Barrett; Megan L Troxell; Christopher P Larsen; Donald C Houghton
Journal:  Int Urol Nephrol       Date:  2013-11-12       Impact factor: 2.370

10.  Clinicopathological characteristics of M-type phospholipase A2 receptor (PLA2R)-related membranous nephropathy in Japanese.

Authors:  Norifumi Hayashi; Shin'ichi Akiyama; Hiroshi Okuyama; Yuki Matsui; Hiroki Adachi; Hideki Yamaya; Shoichi Maruyama; Enyu Imai; Seiichi Matsuo; Hitoshi Yokoyama
Journal:  Clin Exp Nephrol       Date:  2014-12-10       Impact factor: 2.801

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.